Our innovative solutions and dedicated scientists come together to provide industry leading capabilities to take your project from idea to global supply. We don’t just provide the capabilities we also provide extensive regulatory, IP and clinical support. We are committed to positive outcomes and delivering projects on time to specification.
Our biosimilar and novel therapeutics portfolio and pipeline is focused on increasing patient access to much needed therapies and we welcome the opportunity to partner our products with other organizations to co-develop or commercialize these therapeutics.
With state-of-the-art facilities across Europe, Polpharma Biologics is at the forefront of the next wave in biotechnology, leveraging our knowledge, capabilities and footprint to develop innovative solutions for the industry.
Gdańsk
Our Gdansk site includes mammalian and microbial R&D and manufacturing facilities for mid-scale production including drug product and fill finish.
Warsaw
Our Warsaw site is one of the largest biologics manufacturing sites in Europe, with capabilities for preclinical, clinical and commercial supply to EU and US standards.
Utrecht
Our Utrecht site is one of innovation and leads the discovery, optimization and development of novel biologics and biosimilars as well as being home to our industry leading cell line development platform.
Our sites
With state-of-the-art facilities across Europe, Polpharma Biologics is at the forefront of the next wave in biotechnology, leveraging our knowledge, capabilities and footprint to develop innovative solutions for the industry.
Our Gdansk site includes mammalian and microbial R&D and manufacturing facilities for mid-scale production including drug product and fill finish.
Warsaw
Our Warsaw site is one of the largest biologics manufacturing sites in Europe, with capabilities for preclinical, clinical and commercial supply to EU and US standards.
Utrecht
Our Utrecht site is one of innovation and leads the discovery, optimization and development of novel biologics and biosimilars as well as being home to our industry leading cell line development platform.
At Polpharma Biologics, our commitment to excellence begins at the top. With decades of combined experience in the development, manufacture and commercialization of biopharmaceuticals. Our international management team brings both knowledge and passion to every project.
"It is here that new molecules, active substances and drugs for the largest companies in the world are created"
Jerzy Starak
Chairman, Polpharma Biologics Group
“We care about delivering on our commitments”
Hannes Teissl
Vice Chairman, Polpharma Biologics Group
“We are passionate about getting safe and effective medicines to patients”
Dr Joerg Windisch
President & CEO, Polpharma Biologics Group
"We care about delivering on our commitments"
Jan Krzewiński
President, Polpharma Biologics Gdańsk
“We work with dedication and find innovative solutions”
Whether it’s helping our partners accelerate their programs, developing biosimilars to improve patients access or discovering new and innovative medicines to add to our portfolio, all our staff are motivated by the same passion, getting safe and effective medicines to patients. Join us today.
"It is here that new molecules, active substances and drugs for the largest companies in the world are created"
Jerzy Starak is the founder and Chairman of Polpharma Biologics Group B.V. and belongs to the group of Polish entrepreneurs, whose activities contributed to the modernization of the Polish economy. Visionary, who does not lack the courage, determination and perseverance in making difficult business challenges. Thanks to his activity, companies such as Baxter, Bols, Lessafre, Sanofi, Bunge, Nutricia and Colgate-Palmolive, appeared in Poland. In 2000, became the owner of Polpharma S.A. in Starogard Gdanski, joined by Medana Pharma S.A. Sieradz Branch Duchnice purchased from the company Bioton Warsaw Polfa S.A. and the company Sanfarm, transformed into a branch of Production in Nowa Deba.
Hannes Teissl
Vice Chairman, Polpharma Biologics Group
“We care about delivering on our commitments”
Hannes Teissl is the Vice Chairman of Polpharma Biologics Group B.V. He has been with Polpharma Biologics since 2012 and was instrumental in establishing its foundations in Poland as well as the Netherlands (acquisition of Bioceros) and Switzerland (creation of Joint Venture Bioeq AG).
Prior to joining Polpharma Biologics, Hannes has been an Executive Management Board Member at Sandoz, where he held several international management positions over 22 years (e.g. Global Head of Biopharmaceuticals, Global Head of M&A, CEO of Sandoz Germany).
Dr Joerg Windisch
President & CEO, Polpharma Biologics Group
“We are passionate about getting safe and effective medicines to patients”
Dr. Joerg Windisch has around 25 years of experience in the development, manufacture and regulatory licensure of biologic therapies. Since joining Polpharma Biologics, Dr. Windisch has made significant contributions to the organization's formation and growth, and the development of its frontrunner products. Prior to joining Polpharma, Dr. Windisch served as the Chief Operating Officer (COO) for Affimed, a NASDAQ-traded biotech company which develops innovative bi- and trispecific antibodies as immune cell engagers to treat various kinds of cancer. Before that, Dr. Windisch spent almost 20 years at Novartis/Sandoz where he most recently served as Chief Scientific Officer (CSO) for Sandoz Biopharmaceuticals. He was a key figure in developing the first biosimilars approved in Europe and the US.
Jan Krzewiński
President, Polpharma Biologics Gdańsk
"We care about delivering on our commitments"
Jan Krzewinski is the General Manager Gdansk and COO of Polpharma Biologics. Prior to his current position Jan held various roles at Polpharma including the Director of the Chariman’s Strategic Projects Office. Before joining Polpharma he spent almost 9 years working for Mid Europa Partners, the largest CEE-focused private equity fund where he was responsible for executing and monitoring investments. While at Mid Europa Partners Jan held supervisory board-level positions at Lux Med, Diagnostyka, Alpha Medical and Polskie Koleje Linowe. Jan continues to serve on the supervisory boards of Herbapol Lublin and the EFC Educational Foundation. Jan is a graduate of the London School of Economics and Political Science (BSc) and Johns Hopkins University, SAIS (MA).
Frederic Papp
President, Polpharma Biologics Warsaw
“We work with dedication and find innovative solutions”
Frederic Papp is the General Manager Warsaw and CTO of Polpharma Biologics. He has over 25 years of professional experience. Prior to joining Polpharma Biologics, Frederic worked at Merck as Site Head of a Biotech Plant (Spain) as well as Head of Global Biotech Network Operations (Switzerland) alongside performing other senior global and local roles. He earned his MSc in Biology from the Technology University in Dijon (France).
We use cookies
Polpharma Biologics uses cookies and other similar technologies (hereinafter: cookies) on its webpages and mobile applications (hereinafter, jointly, Website). The user can manage cookies independently by changing the web browser settings. If you do not consent for your personal data to be collected via cookies, you should change your web browser settings or stop using the Website.
Using the Website without changing the web browser settings indicates your acceptance of the use of cookies by Polpharma. Acceptance of the web browser settings indicates your consent to profiling on the basis of the information contained in cookies. Consent may be withdrawn at any time. Withdrawal of consent does not affect lawfulness of any processing activities carried out under consent before its withdrawal.